Patents by Inventor Branislav Musicki

Branislav Musicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF
    Publication number: 20230382906
    Abstract: Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 30, 2023
    Inventors: Gilles OUVRY, Branislav MUSICKI, Craig HARRIS, Claire BOUIX-PETER, Marie-Hélène FOUCHET, Nicolas GEORGE
  • JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF
    Publication number: 20230279003
    Abstract: Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 7, 2023
    Inventors: Gilles OUVRY, Branislav MUSICKI, Craig HARRIS, Claire BOUIX-PETER, Marie-Hélène FOUCHET, Nicolas GEORGE
  • NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF
    Publication number: 20230212188
    Abstract: Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
    Type: Application
    Filed: March 13, 2023
    Publication date: July 6, 2023
    Inventors: Gilles OUVRY, Branislav MUSICKI, Craig HARRIS, Etienne Thoreau
  • Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
    Patent number: 10752617
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: August 25, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
    Patent number: 10647706
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: May 12, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Yushma Bhurruth-Alcor
  • Benzimidazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (T))
    Patent number: 10618890
    Abstract: Benzimidazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 14, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • Tetrahydroquinoline sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR gamma (t))
    Patent number: 10550110
    Abstract: Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (ROR?t) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Claire Bouix-Peter, Gilles Ouvry, Etienne Thoreau
  • Benzenesulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR?(T))
    Patent number: 10457637
    Abstract: Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (ROR?t) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: October 29, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Claire Bouix-Peter, Gilles Ouvry, Etienne Thoreau
  • NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES
    Publication number: 20190225598
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav MUSICKI, Yushma BHURRUTH-ALCOR
  • INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20190202819
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
    Patent number: 10287278
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 14, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Yushma Bhurruth-Alcor
  • Indazole sulfonamide derivatives as inverse agonists of retinoid-related orphan receptor gamma (ROR ? (T))
    Patent number: 10246440
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 2, 2019
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Gilles Ouvry, Etienne Thoreau, Claire Bouix-Peter
  • BENZIMIDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20190071433
    Abstract: Benzimidazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: March 7, 2019
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • TETRAHYDROQUINOLINE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20180265500
    Abstract: Tetrahydroquinoline sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma (ROR?t) are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: September 20, 2018
    Inventors: Branislav MUSICKI, Claire BOUIX-PETER, Gilles OUVRY, Etienne THOREAU
  • BENZENESULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20180170869
    Abstract: Benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonist of retinoid-related orphan receptor gamma (ROR?t) are described. A pharmaceutical composition including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-medicated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 21, 2018
    Inventors: Branislav MUSICKI, Claire BOUIX-PETER, Gilles OUVRY, Etienne THOREAU
  • NOVEL CHEMOKINE CXCR1 AND CXCR2 RECEPTOR ANTAGONIST COMPOUNDS, AND USE THEREOF IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES
    Publication number: 20170349575
    Abstract: Novel chemokine CXCR1 and CXCR2 receptor antagonist compounds of general formula (I) are described. Also described, are pharmaceutical compositions including the compounds, and use of the compounds and the compositions for the treatment of chemokine-mediated pathologies, more specifically in the field of dermatology.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 7, 2017
    Inventors: Branislav MUSICKI, Yushma BHURRUTH-ALCOR
  • INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
    Publication number: 20170342062
    Abstract: Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma ROR?t are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of ROR?t receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 30, 2017
    Inventors: Branislav MUSICKI, Gilles OUVRY, Etienne THOREAU, Claire BOUIX-PETER
  • Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate
    Patent number: 9650337
    Abstract: A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: May 16, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Jean-Guy Boiteau, Branislav Musicki
  • Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
    Patent number: 9580412
    Abstract: Methods for preparing disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds that correspond to general formula (I) are described. Also described are pharmaceutical compositions that include the compounds, and methods of using the compounds and compositions for the treatment of chemokine-mediated diseases.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: February 28, 2017
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteau, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
    Patent number: 9526732
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds represented by the general formula (I) are described. Also described, are pharmaceutical compositions including these compounds and the use of these compounds and compositions for the treatment of chemokine-mediated pathologies.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 27, 2016
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteau, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet